What is the Price/FCF ratio for Intellia Therapeutics, Inc. (NTLA)?

The Price/FCF ratio for NTLA stock is N/A.

What is the estimated TTM average Price/FCF ratio for Intellia Therapeutics, Inc. (NTLA)?

The estimated TTM average Price/FCF ratio for NTLA stock is 13.58.

Compare

Intellia Therapeutics, Inc.(NTLA)

Biotechnology · Cambridge, MA

$12.28+0.16 (+1.28%)

Delayed quote: Oct 2, 2026, 3:40 PM EDT

Compare

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-02T19:40:47.990Z.

Stored calculation inputs

Calculation as of: 2026-10-02T19:40:47.990Z.

Quote observation: 2026-10-02T19:40:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,715,090,864
TTM free cash flow · period ending 2026-06-30: -348,686,000

FMP input reference: cfe467dbfbd77c451c9134e6671c17e93f9075fb3089474378ac41e20d4454d7

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Price/FCF Ratio

NTLA Price/FCF Ratio Chart

N/A

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2017-08-01.

NTLA Price/FCF Ratio

NTLA Average Price/FCF Ratio Chart

NTLA Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

PRICE/FCF RATIO AVG TTM

13.58

PRICE/FCF RATIO AVG 3Y

N/A

PRICE/FCF RATIO AVG 5Y

N/A

PRICE/FCF RATIO AVG 10Y

N/A

PRICE/FCF RATIO AVG 15Y

N/A

PRICE/FCF RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

NTLA Competitors' Price/FCF Ratio

NTLA

Intellia Therapeutics, Inc.

Current

Market Cap

$1.72B

Price/FCF Ratio

N/A

TTM Avg

13.58

3Y Avg

N/A

5Y Avg

N/A

XRAY

DENTSPLY SIRONA Inc.

vs NTLA

Market Cap

$1.73B

Price/FCF Ratio

12.08

TTM Avg

22.94

3Y Avg

20.46

5Y Avg

20.08

RXRX

Recursion Pharmaceuticals, Inc.

vs NTLA

Market Cap

$2.14B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TDOC

Teladoc Health, Inc.

vs NTLA

Market Cap

$1.00B

Price/FCF Ratio

4.45

TTM Avg

5.51

3Y Avg

6.85

5Y Avg

13.80

BEAM

Beam Therapeutics Inc.

vs NTLA

Market Cap

$2.51B

Price/FCF Ratio

N/A

TTM Avg

44.80

3Y Avg

44.80

5Y Avg

44.80

TMDX

TransMedics Group, Inc.

vs NTLA

Market Cap

$2.74B

Price/FCF Ratio

34.64

TTM Avg

55.51

3Y Avg

87.60

5Y Avg

87.60

NEO

NeoGenomics, Inc.

vs NTLA

Market Cap

$472.39M

Price/FCF Ratio

N/A

TTM Avg

53.25

3Y Avg

37.33

5Y Avg

28.89

NRC

NRC Health

vs NTLA

Market Cap

$459.30M

Price/FCF Ratio

21.22

TTM Avg

27.48

3Y Avg

28.67

5Y Avg

30.19

Shoulder Innovations, Inc.

vs NTLA

Market Cap

$397.55M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs NTLA

Market Cap

$41.03M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Intellia Therapeutics, Inc. (NTLA)	$1.72B	N/A	13.58	N/A	N/A
DENTSPLY SIRONA Inc. (XRAY)vs ›	$1.73B	12.08	22.94	20.46	20.08
Recursion Pharmaceuticals, Inc. (RXRX)vs ›	$2.14B	N/A	N/A	N/A	N/A
Teladoc Health, Inc. (TDOC)vs ›	$1.00B	4.45	5.51	6.85	13.80
Beam Therapeutics Inc. (BEAM)vs ›	$2.51B	N/A	44.80	44.80	44.80
TransMedics Group, Inc. (TMDX)vs ›	$2.74B	34.64	55.51	87.60	87.60
NeoGenomics, Inc. (NEO)vs ›	$472.39M	N/A	53.25	37.33	28.89
NRC Health (NRC)vs ›	$459.30M	21.22	27.48	28.67	30.19
Shoulder Innovations, Inc. (SI)vs ›	$397.55M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$41.03M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio FAQ

What is the Price/FCF ratio for Intellia Therapeutics, Inc. (NTLA)?: The Price/FCF ratio for NTLA stock is N/A.
What is the estimated TTM average Price/FCF ratio for Intellia Therapeutics, Inc. (NTLA)?: The estimated TTM average Price/FCF ratio for NTLA stock is 13.58.

NTLA Price/FCF Ratio History

DATE	PRICE/FCF RATIO
2017-08-01	22.54
2017-07-31	23.57
2017-07-28	23.85
2017-07-27	23.24
2017-07-26	23.83
2017-07-25	23.66
2017-07-24	24.29
2017-07-21	22.96
2017-07-20	23.12
2017-07-19	22.80
2017-07-18	21.79
2017-07-17	23.26
2017-07-14	24.15
2017-07-13	23.69
2017-07-12	23.31
2017-07-11	22.59
2017-07-10	22.47
2017-07-07	23.20
2017-07-06	23.69
2017-07-05	24.04
2017-07-03	22.92
2017-06-30	22.39
2017-06-29	22.73
2017-06-28	23.82
2017-06-27	22.42
2017-06-26	22.82
2017-06-23	21.13
2017-06-22	21.41
2017-06-21	20.91
2017-06-20	19.10
2017-06-19	19.69
2017-06-16	17.23
2017-06-15	17.24
2017-06-14	17.69
2017-06-13	17.90
2017-06-12	17.81
2017-06-09	17.63
2017-06-08	17.62
2017-06-07	16.71
2017-06-06	16.76
2017-06-05	17.28
2017-06-02	17.35
2017-06-01	17.07
2017-05-31	16.04
2017-05-30	15.93
2017-05-26	18.57
2017-05-25	19.03
2017-05-24	20.19
2017-05-23	19.94
2017-05-22	19.82
2017-05-19	20.00
2017-05-18	20.08
2017-05-17	19.45
2017-05-16	20.65
2017-05-15	21.26
2017-05-12	20.54
2017-05-11	19.54
2017-05-10	19.90
2017-05-09	19.47
2017-05-08	18.84
2017-05-05	19.09
2017-05-04	18.99
2017-05-03	19.45
2017-05-02	16.73
2017-05-01	17.61
2017-04-28	16.79
2017-04-27	17.18
2017-04-26	17.41
2017-04-25	16.49
2017-04-24	16.25
2017-04-21	15.94
2017-04-20	16.71
2017-04-19	16.35
2017-04-18	16.61
2017-04-17	16.70
2017-04-13	16.04
2017-04-12	15.53
2017-04-11	15.96
2017-04-10	15.83
2017-04-07	15.75
2017-04-06	15.86
2017-04-05	16.32
2017-04-04	17.30
2017-04-03	16.77
2017-03-31	16.24
2017-03-30	15.85
2017-03-29	15.81
2017-03-28	15.64
2017-03-27	15.19
2017-03-24	15.06
2017-03-23	15.20
2017-03-22	14.99
2017-03-21	15.04
2017-03-20	16.54
2017-03-17	16.57
2017-03-16	16.57
2017-03-15	15.81
2017-03-14	11.26
2017-03-13	11.84
2017-03-10	11.69
2017-03-09	11.43
2017-03-08	11.23
2017-03-07	10.80
2017-03-06	10.87
2017-03-03	11.47
2017-03-02	12.63
2017-03-01	12.42
2017-02-28	11.83
2017-02-27	11.10
2017-02-24	10.15
2017-02-23	10.50
2017-02-22	10.70
2017-02-21	11.03
2017-02-17	11.22
2017-02-16	11.14
2017-02-15	10.36
2017-02-14	11.42
2017-02-13	10.94
2017-02-10	10.76
2017-02-09	10.76
2017-02-08	10.50
2017-02-07	10.85
2017-02-06	11.02
2017-02-03	11.08
2017-02-02	11.03
2017-02-01	11.18
2017-01-31	10.70
2017-01-30	10.41
2017-01-27	10.44
2017-01-26	10.05
2017-01-25	10.43
2017-01-24	10.30
2017-01-23	10.33
2017-01-20	10.47
2017-01-19	10.70
2017-01-18	10.80
2017-01-17	10.87
2017-01-13	11.33
2017-01-12	11.09
2017-01-11	11.47
2017-01-10	12.15
2017-01-09	11.85
2017-01-06	11.50
2017-01-05	11.46
2017-01-04	11.61
2017-01-03	11.17
2016-12-30	10.86
2016-12-29	10.99
2016-12-28	11.18
2016-12-27	11.92
2016-12-23	12.30
2016-12-22	11.98
2016-12-21	13.35
2016-12-20	13.21
2016-12-19	13.14
2016-12-16	13.53
2016-12-15	13.25
2016-12-14	13.21
2016-12-13	13.21
2016-12-12	13.42
2016-12-09	13.31
2016-12-08	12.74
2016-12-07	12.69
2016-12-06	13.26
2016-12-05	13.28
2016-12-02	13.15
2016-12-01	12.87
2016-11-30	13.05
2016-11-29	13.59
2016-11-28	14.04
2016-11-25	14.29
2016-11-23	14.07
2016-11-22	14.08
2016-11-21	14.74
2016-11-18	13.87
2016-11-17	13.76
2016-11-16	14.53
2016-11-15	15.00
2016-11-14	13.46
2016-11-11	12.26
2016-11-10	11.92
2016-11-09	11.93
2016-11-08	12.27
2016-11-07	12.15
2016-11-04	11.54
2016-11-03	10.81
2016-11-02	10.76
2016-11-01	5.68
2016-10-31	5.76
2016-10-28	5.41
2016-10-27	5.39
2016-10-26	5.92
2016-10-25	5.77
2016-10-24	6.29
2016-10-21	5.76
2016-10-20	5.21
2016-10-19	5.27
2016-10-18	5.02
2016-10-17	5.17
2016-10-14	5.37
2016-10-13	5.67
2016-10-12	5.16
2016-10-11	5.48
2016-10-10	6.03
2016-10-07	6.31
2016-10-06	6.91
2016-10-05	7.24
2016-10-04	6.89
2016-10-03	6.97
2016-09-30	7.11
2016-09-29	7.10
2016-09-28	7.11
2016-09-27	7.07
2016-09-26	7.06
2016-09-23	7.23
2016-09-22	7.52
2016-09-21	7.81
2016-09-20	8.06
2016-09-19	7.96
2016-09-16	8.24
2016-09-15	8.25
2016-09-14	8.52
2016-09-13	8.27
2016-09-12	8.63
2016-09-09	8.81
2016-09-08	9.11
2016-09-07	8.29
2016-09-06	8.26
2016-09-02	8.28
2016-09-01	8.30
2016-08-31	8.13
2016-08-30	8.40
2016-08-29	8.32
2016-08-26	8.74
2016-08-25	8.84
2016-08-24	8.81
2016-08-23	10.24
2016-08-22	9.42
2016-08-19	9.32
2016-08-18	9.52
2016-08-17	9.67
2016-08-16	9.06
2016-08-15	7.91
2016-08-12	7.66
2016-08-11	7.47
2016-08-10	7.49
2016-08-09	7.84
2016-08-08	8.09
2016-08-05	8.44

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

Cambridge, MA

377 employees

www.intelliatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Leonard

View full financials

NAME

MARKET CAP

PRICE/FCF RATIO

TTM

Intellia Therapeutics, Inc. (NTLA)

$1.72B

N/A

13.58

N/A

DENTSPLY SIRONA Inc. (XRAY)vs ›

$1.73B

12.08

22.94

20.46

20.08

Recursion Pharmaceuticals, Inc. (RXRX)vs ›

$2.14B

N/A

Teladoc Health, Inc. (TDOC)vs ›

$1.00B

4.45

5.51

6.85

13.80

Beam Therapeutics Inc. (BEAM)vs ›

$2.51B

N/A

44.80

TransMedics Group, Inc. (TMDX)vs ›

$2.74B

34.64

55.51

87.60

NeoGenomics, Inc. (NEO)vs ›

$472.39M

N/A

53.25

37.33

28.89

NRC Health (NRC)vs ›

$459.30M

21.22

27.48

28.67

30.19

Shoulder Innovations, Inc. (SI)vs ›

$397.55M

N/A

PDS Biotechnology Corporation (PDSB)vs ›

$41.03M

N/A

DATE

PRICE/FCF RATIO

2017-08-01

22.54

2017-07-31

23.57

2017-07-28

23.85

2017-07-27

23.24

2017-07-26

23.83

2017-07-25

23.66

2017-07-24

24.29

2017-07-21

22.96

2017-07-20

23.12

2017-07-19

22.80

2017-07-18

21.79

2017-07-17

23.26

2017-07-14

24.15

2017-07-13

23.69

2017-07-12

23.31

2017-07-11

22.59

2017-07-10

22.47

2017-07-07

23.20

2017-07-06

23.69

2017-07-05

24.04

2017-07-03

22.92

2017-06-30

22.39

2017-06-29

22.73

2017-06-28

23.82

2017-06-27

22.42

2017-06-26

22.82

2017-06-23

21.13

2017-06-22

21.41

2017-06-21

20.91

2017-06-20

19.10

2017-06-19

19.69

2017-06-16

17.23

2017-06-15

17.24

2017-06-14

17.69

2017-06-13

17.90

2017-06-12

17.81

2017-06-09

17.63

2017-06-08

17.62

2017-06-07

16.71

2017-06-06

16.76

2017-06-05

17.28

2017-06-02

17.35

2017-06-01

17.07

2017-05-31

16.04

2017-05-30

15.93

2017-05-26

18.57

2017-05-25

19.03

2017-05-24

20.19

2017-05-23

19.94

2017-05-22

19.82

2017-05-19

20.00

2017-05-18

20.08

2017-05-17

19.45

2017-05-16

20.65

2017-05-15

21.26

2017-05-12

20.54

2017-05-11

19.54

2017-05-10

19.90

2017-05-09

19.47

2017-05-08

18.84

2017-05-05

19.09

2017-05-04

18.99

2017-05-03

19.45

2017-05-02

16.73

2017-05-01

17.61

2017-04-28

16.79

2017-04-27

17.18

2017-04-26

17.41

2017-04-25

16.49

2017-04-24

16.25

2017-04-21

15.94

2017-04-20

16.71

2017-04-19

16.35

2017-04-18

16.61

2017-04-17

16.70

2017-04-13

16.04

2017-04-12

15.53

2017-04-11

15.96

2017-04-10

15.83

2017-04-07

15.75

2017-04-06

15.86

2017-04-05

16.32

2017-04-04

17.30

2017-04-03

16.77

2017-03-31

16.24

2017-03-30

15.85

2017-03-29

15.81

2017-03-28

15.64

2017-03-27

15.19

2017-03-24

15.06

2017-03-23

15.20

2017-03-22

14.99

2017-03-21

15.04

2017-03-20

16.54

2017-03-17

16.57

2017-03-16

16.57

2017-03-15

15.81

2017-03-14

11.26

2017-03-13

11.84

2017-03-10

11.69

2017-03-09

11.43

2017-03-08

11.23

2017-03-07

10.80

2017-03-06

10.87

2017-03-03

11.47

2017-03-02

12.63

2017-03-01

12.42

2017-02-28

11.83

2017-02-27

11.10

2017-02-24

10.15

2017-02-23

10.50

2017-02-22

10.70

2017-02-21

11.03

2017-02-17

11.22

2017-02-16

11.14

2017-02-15

10.36

2017-02-14

11.42

2017-02-13

10.94

2017-02-10

10.76

2017-02-09

10.76

2017-02-08

10.50

2017-02-07

10.85

2017-02-06

11.02

2017-02-03

11.08

2017-02-02

11.03

2017-02-01

11.18

2017-01-31

10.70

2017-01-30

10.41

2017-01-27

10.44

2017-01-26

10.05

2017-01-25

10.43

2017-01-24

10.30

2017-01-23

10.33

2017-01-20

10.47

2017-01-19

10.70

2017-01-18

10.80

2017-01-17

10.87

2017-01-13

11.33

2017-01-12

11.09

2017-01-11

11.47

2017-01-10

12.15

2017-01-09

11.85

2017-01-06

11.50

2017-01-05

11.46

2017-01-04

11.61

2017-01-03

11.17

2016-12-30

10.86

2016-12-29

10.99

2016-12-28

11.18

2016-12-27

11.92

2016-12-23

12.30

2016-12-22

11.98

2016-12-21

13.35

2016-12-20

13.21

2016-12-19

13.14

2016-12-16

13.53

2016-12-15

13.25

2016-12-14

13.21

2016-12-13

13.21

2016-12-12

13.42

2016-12-09

13.31

2016-12-08

12.74

2016-12-07

12.69

2016-12-06

13.26

2016-12-05

13.28

2016-12-02

13.15

2016-12-01

12.87

2016-11-30

13.05

2016-11-29

13.59

2016-11-28

14.04

2016-11-25

14.29

2016-11-23

14.07

2016-11-22

14.08

2016-11-21

14.74

2016-11-18

13.87

2016-11-17

13.76

2016-11-16

14.53

2016-11-15

15.00

2016-11-14

13.46

2016-11-11

12.26

2016-11-10

11.92

2016-11-09

11.93

2016-11-08

12.27

2016-11-07

12.15

2016-11-04

11.54

2016-11-03

10.81

2016-11-02

10.76

2016-11-01

5.68

2016-10-31

5.76

2016-10-28

5.41

2016-10-27

5.39

2016-10-26

5.92

2016-10-25

5.77

2016-10-24

6.29

2016-10-21

5.76

2016-10-20

5.21

2016-10-19

5.27

2016-10-18

5.02

2016-10-17

5.17

2016-10-14

5.37

2016-10-13

5.67

2016-10-12

5.16

2016-10-11

5.48

2016-10-10

6.03

2016-10-07

6.31

2016-10-06

6.91

2016-10-05

7.24

2016-10-04

6.89

2016-10-03

6.97

2016-09-30

7.11

2016-09-29

7.10

2016-09-28

7.11

2016-09-27

7.07

2016-09-26

7.06

2016-09-23

7.23

2016-09-22

7.52

2016-09-21

7.81

2016-09-20

8.06

2016-09-19

7.96

2016-09-16

8.24

2016-09-15

8.25

2016-09-14

8.52

2016-09-13

8.27

2016-09-12

8.63

2016-09-09

8.81

2016-09-08

9.11

2016-09-07

8.29

2016-09-06

8.26

2016-09-02

8.28

2016-09-01

8.30

2016-08-31

8.13

2016-08-30

8.40

2016-08-29

8.32

2016-08-26

8.74

2016-08-25

8.84

2016-08-24

8.81

2016-08-23

10.24

2016-08-22

9.42

2016-08-19

9.32

2016-08-18

9.52

2016-08-17

9.67

2016-08-16

9.06

2016-08-15

7.91

2016-08-12

7.66

2016-08-11

7.47

2016-08-10

7.49

2016-08-09

7.84

2016-08-08

8.09

2016-08-05

8.44

Price/FCF Ratio: N/A

NTLA Price/FCF Ratio Chart

NTLA Average Price/FCF Ratio Chart

NTLA Price/FCF Ratio Metrics

NTLA Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Price/FCF Ratio FAQ

NTLA Price/FCF Ratio History

Related Metrics

Price/FCF Ratio: N/A

NTLA Price/FCF Ratio Chart

NTLA Average Price/FCF Ratio Chart

NTLA Price/FCF Ratio Metrics

NTLA Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Price/FCF Ratio FAQ

NTLA Price/FCF Ratio History

Related Metrics